Description
SARS-CoV-2 Spike V483A mutant Cell Line stable expresses SARS-CoV-2 Spike Glycoprotein encoding a V483A mutation. Coronaviruses (CoVs) infect human and animals and cause varieties of diseases, such as respiratory, enteric, renal, and neurological diseases. V483A mutation has the potential to change the protein secondary structure and relative solvent accessibility in the RBM region (Ref. 1).
SARS-CoV-2 uses its spike glycoprotein (S), a main target for neutralization antibody, to bind its receptor, and mediate membrane fusion and virus entry. It uses human ACE2 to enter cells, correlating with the efficient spread of SARS-CoV-2 among humans. S comprises two functional subunits responsible for binding to the host cell receptor (S1 subunit) and also fusion of the viral and cellular membranes (S2 subunit). The cell line also allows the study of SARS-CoV-2 spike/ ACE2 interaction in cell-based assays.
SARS-CoV-2 Spike V483A mutant cell line, developed stably transfecting HEK293 cell line with a SARS-CoV-2 Spike V483A mutant expression plasmid, provides consistent levels of expression of human SARS-CoV-2 Spike V483A mutant in cells surface. Each vial of cells contains more than 3 million viable cells stably expressing SARS-CoV-2 Spike V483A mutant with hygromycin resistance gene.
This Spike V483A mutant cell line is ready to use in cell-based assay applications. This cell line also allow to establish in vitro models for High Throughput and High Content Screening.
Reviews
There are no reviews yet.